ONCOLOGY AND CRITICAL CARE NICHE EXPERTISE &
LARGEST PRODUCT BASKET
PARTNER OF CHOICE SUPPLIER TO LEADING HOSPITAL
CHAINS & GOVT. INSTITUTIONS
MADE IN INDIA 46+ ROW MARKETS
650+ PRODUCTS REGISTRATIONS
WELL BEING WITH EVERY NOVEL DRUG,
SOMEONE, SOMEWHERE IS GETTING CLOSER TO

Welcome to Celon , we are one of India’s leading specialty biopharmaceutical company at the forefront of research, manufacturing and marketing of high quality formulations in niche therapy areas of Oncology and Critical Care.

Celon is a specialty focused biopharmaceutical company with core competencies in developing innovative, non-infringing, cost effective solutions. Celon adheres to global quality standards – catering to both Indian and ROW markets.

With our science and pharmaceutical expertise, we have brought a range of products from laboratory to the market and continue to do so, making medicines more accessible to people and in markets where it is most needed.

Our growing portfolio of Oncology and Critical Care products reflect our continued commitment to deliver quality treatment across the globe.

Celon – Research and Beyond

Our cutting-edge work in Novel Drug Delivery Systems include platform technologies such as Microspheres, Liposomal and Nanoparticulate formulations.

Celon – Capable and Committed

Celon works in niche therapy segments, a space that demands advanced manufacturing capabilities. To that end, we equip ourselves with the best-in-class technology and the best-in-segment practices.

LAUNCHED INDIA’S FIRST INDIGENOUS BONE MARROW TRANSPLANT RANGE

Celon Milestones

2007
LAUNCHED VIVILON—OUR ONCOLOGY FOCUSSED OFFERING— WITH COMPREHENSIVE ORAL RANGE
2008
>> SET UP STATE-OF-THE-ART CYTOTOXIC SMALL VOLUME PARENTERAL FACILITY WITH WHO-GMP AND SCHEDULE M CERTIFICATION

>> LAUNCHED BUSINESS OPERATIONS IN ROW MARKETS

2009
>> LAUNCHED INDIA’S FIRST BONE MARROW TRANSPLANT RANGE

>> LAUNCHED REVILON - OUR CRITICAL CARE FOCUSSED OFFERING WITH A VITAL PRODUCT PORTFOLIO FOR CARDIOVASCULAR AND ANAESTHESIA SEGMENT

2011
STRENGHTENED THE R&D FACILITY TO CATER TO CURRENT MARKET REQUIREMENTS
2013
GLOBAL PRESENCE ACROSS 50+ COUNTRIES COMMMERCIALIZED PRODUCTS IN ALL FOUR GEOGRAPHIES (LATAM, CIS, AFRICA, SEA)
2015
Developed Leuprolide Acetate Depot Formulation WITH sustained release innovation
2017
LAUNCHED unique FIRST time in India MOLECULES like Etomidate, Bendamustine rapid infusion & Tegafur + UracIl. Prestigious products like Nanosomal Albumin bound Paclitaxel & OCTREOTIDE DEPOT
2020
ACQUISITION BY UK BASED INVESTORS
2021
LAUNCHED AMPHOTERICIN B EMULSION - AN ALTERNATIVE DRUG TO TREAT MUCORMYCOSIS

Corporate Video

Play Video

Enquire Now